Get the Stockscreener App
25.91
0.42%
-0.11
After Hours:
26.15
0.24
+0.93%
Greenwich Lifesciences Inc stock is traded at $25.91, with a volume of 79,489.
It is down -0.42% in the last 24 hours and down -3.10% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$26.02
Open:
$25.95
24h Volume:
79,489
Relative Volume:
0.24
Market Cap:
$358.97M
Revenue:
-
Net Income/Loss:
$-19.48M
P/E Ratio:
-17.70
EPS:
-1.4641
Net Cash Flow:
$-8.59M
1W Performance:
+7.07%
1M Performance:
-3.10%
6M Performance:
+150.82%
1Y Performance:
+189.50%
1-Day Range:
$25.40
$26.69
1-Week Range:
$24.01
$28.15
52-Week Range:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
25.91 | 360.50M | 0 | -19.48M | -8.59M | -1.4641 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Greenwich Lifesciences Provides Clinical Trial and Pipeline Update - National Today
Strategic financing update revealed by Greenwich LifeSciences - Traders Union
Greenwich LifeSciences reports Q1 cash balance of $10.5 million By Investing.com - Investing.com India
Greenwich LifeSciences, Inc. Provides Financial Updates and Progress on FLAMINGO-01 Phase III Trial for Breast Cancer Immunotherapy GLSI-100 - Quiver Quantitative
Greenwich LifeSciences reports Q1 cash balance of $10.5 million - Investing.com
Greenwich LifeSciences Provides Update on Financing Strategy - ChartMill
Portfolio Shifts: Can Greenwich LifeSciences Inc expand into new markets2026 Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Greenwich Lifesciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView — Track All Markets
Aug Retail: Will Greenwich LifeSciences Inc benefit from current market trendsTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Will Greenwich LifeSciences Inc benefit from current market trends2026 Market Outlook & Weekly Hot Stock Watchlists - baoquankhu1.vn
(GLSI) Risk Channels and Responsive Allocation - Stock Traders Daily
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 - ADVFN
GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim - Seeking Alpha
Greenwich LifeSciences files patent claims for breast cancer therapy By Investing.com - Investing.com South Africa
Greenwich LifeSciences advances new patent claims after FLAMINGO-01 data show statistically significant immune response - Traders Union
Greenwich LifeSciences files patent claims for breast cancer therapy - Investing.com
Greenwich Lifesciences Provides Update On Patent Claims Potentially Doubling Gp2 Market Potential - TradingView
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential - The Manila Times
Greenwich LifeSciences Provides Update On Patent Claims Potentially Doubling GP2 Market Potential - marketscreener.com
Valuation Update: Can Greenwich LifeSciences Inc expand into new marketsMarket Sentiment Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Greenwich LifeSciences Delays Annual SEC Filing - TipRanks
Greenwich LifeSciences (GLSI) notifies SEC of late 10-K, cites higher R&D - Stock Titan
Sell Signal: What are the future prospects of Greenwich LifeSciences Inc2026 Market Overview & Long-Term Investment Growth Plans - baoquankhu1.vn
(GLSI) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Aug Analyst Calls: What are the future prospects of Greenwich LifeSciences IncPortfolio Value Summary & Real-Time Market Trend Scan - baoquankhu1.vn
Why Is GLSI Stock Rising Today? - Dailyhunt
If You Invested $1,000 in Greenwich Lifesciences Inc (GLSI) - Stock Titan
Retail Trends: Is Greenwich LifeSciences Inc undervalued by DCF analysisGold Moves & Weekly Top Performers Watchlists - baoquankhu1.vn
Treasury Yields: Is Greenwich LifeSciences Inc a turnaround storyWeekly Profit Analysis & Long Hold Capital Preservation Plans - baoquankhu1.vn
Greenwich LifeSciences expands Phase III trial to City of Hope sites - ca.investing.com
Greenwich LifeSciences Inc initiates new US clinical sites for Flamingo-01 phase III trial - marketscreener.com
Greenwich LifeSciences, Inc. Announces Addition of City of Hope to Flamingo-01 - marketscreener.com
Greenwich LifeSciences Expands FLAMINGO-01 Trial to City of Hope - National Today
Greenwich LifeSciences expands Phase III trial to City of Hope sites By Investing.com - Investing.com India
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 - ChartMill
Liquidity Mapping Around (GLSI) Price Events - Stock Traders Daily
Greenwich LifeSciences to present trial data at AACR meeting By Investing.com - Investing.com South Africa
Greenwich LifeSciences to present trial data at AACR meeting - Investing.com
Greenwich Lifesciences provides update on upcoming AACR meeting - marketscreener.com
Greenwich Lifesciences Provides Update On Upcoming Aacr Meeting - TradingView
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting - manilatimes.net
Greenwich LifeSciences, Inc. Announces Presentation of FLAMINGO-01 Phase III Clinical Trial Data at AACR Meeting 2026 - Quiver Quantitative
Greenwich LifeSciences to share AACR Meeting plans - Traders Union
Greenwich LifeSciences reports reduced cancer recurrence in trial By Investing.com - Investing.com South Africa
Why is GLSI stock rising today? - MSN
Breakthrough in Clinical Trial Data: Biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ: GLSI) recently announced the latest analysis results of its core immunotherapy GP2 in adjuvant treatment for breast cancer. - Bitget
Greenwich LifeSciences reports reduced cancer recurrence in trial - Investing.com
Greenwich LifeSciences provides update showing continued reduction in recurrence rate in the open label arm of Flamingo-01 - marketscreener.com
Greenwich Lifesciences Provides Update Showing Continued Reduction In Recurrence Rate In The Open Label Arm Of Flamingo-01 - TradingView
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):